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ABSTRACT
Objective: The present study aimed to evaluate the association between glycemic control and quality of life (QoL) in people with type 2 diabetes 
mellitus (T2DM) and identify that factors that influence glycemic control and QoL.
Methods: This cross-sectional study was conducted at the general hospital in Depok City from October to December 2017. Respondents were 
outpatients diagnosed with T2DM, receiving routine care at the hospital. Glycemic control was assessed using glycated hemoglobin (HbA1c) levels, 
while QoL was measured using an Indonesian version of the validated 5-level EuroQol 5-Dimensional.
Results: Among 108 participants, HbA1c levels were influenced by age, DM disease duration, DM treatment adherence, glycemic control, diet, and 
physical activity suitable for patients with DM. The mean QoL value was 0.74±0.23 and the visual analog scale (VAS) score was 65.49±15.96. The QoL 
values of patients with DM were influenced by HbA1c levels, duration of DM, and physical activity, while the VAS score was significantly affected by 
HbA1c levels and duration of DM.
Conclusion: The present study showed that the QoL of T2DM patients was significantly influenced by glycemic control and other factors.
Keywords: Type 2 diabetes mellitus, Quality of life, Hemoglobin A1c, Glycemic control, 5-Level EuroQol 5-dimensional.
INTRODUCTION
Diabetes mellitus (DM) is a chronic disease worldwide that can lead 
to disabilities and even death. In 2014, the World Health Organization 
(WHO) stated that there were as many as 422 million people worldwide 
with the disease, with a prevalence of 8.5% [1]. The prevalence of DM 
in Indonesia is 2.1%, based on the Basic Health Research and the WHO 
data, showing that DM is the third leading cause of death in Indonesia, 
with 100,400 cases (6.5%) in 2012 [2,3]. DM is a chronic disease 
that requires long-term therapy and management, including self-
care behaviors. Patients with type 2 diabetes mellitus (T2DM) show 
symptoms of age-related depression, functional disabilities, diabetes 
duration, disease complications, and sociodemographic factors that 
affect the quality of life (QoL) [4,5].
Measurements of glycemic control using glycated hemoglobin 
(HbA1c) values and self-monitoring of blood glucose at health-
care facilities are used to assess the effectiveness and safety of 
DM therapy. HbA1c monitoring should be performed routinely 
for all patients with DM, with a target of <7% in non-pregnant 
adult patients [6]. HbA1c levels are influenced by gender, race, 
health insurance, DM duration, physical activity, and language 
understanding, whereas marital status, self-control of glucose, type 
of DM therapy, and antihypertensive and anticholesterol drug use 
do not significantly affect this index [6-8]. QoL is affected by age, 
gender, race, comorbidities, occupational status, and educational 
level [6]. Low glycemic control also affects the QoL of patients with 
diabetes, although some studies suggest that the QoL of patients 
with DM is not affected by HbA1c levels [9-13].
The 5-level EuroQol 5-Dimensional (EQ-5D-5L) is a standard QoL 
assessment tool that was developed by the EuroQol Group and has 
various language versions. Other versions of the EQ-5D include 
the EQ-5D-3L and EQ-5D-Y, which can be used for adolescent 
patients [14]. A study comparing EQ-5D-5L and EQ-5D-3L concluded 
that the EQ-5D-5L version had a much higher distinguishing power 
than the EQ-5D-3L device for patients with diabetes [5].
In 2017, the Indonesian version of the EQ-5D-5L QoL instrument was 
translated, validated, standardized, evaluated, and published for use 
as a health-related QoL tool in Indonesia [15]. The determined value 
set for a descriptive questionnaire can affect the value of life quality. 
The EQ-5D value set was compared with the EQ-5D-3L questionnaire 
used for cervical cancer patients in Indonesia and showed significant 
differences in the use of the four values set [16].
In the West Java Province of Indonesia, the prevalence of diabetes in 
individuals ≥15 years of age is 2.0%, which is increased from the prevalence 
of 1.3% reported in 2007. In Depok City, West Java, DM is the third most 
common non-communicable disease, with 21,971 cases reported in 
2015 [10]. This high rate of DM seen at the general hospital in Depok City, 
a secondary health care facility, has drawn attention to patients with DM. 
To date, no studies have assessed health-related QoL and its association 
with glucose control in patients with DM at the general hospital in Depok 
City. Therefore, it is necessary to evaluate the association between glycemic 
control and QoL in patients with DM and to identify the influencing factors.
METHODS
The study was cross-sectional in design and was carried out at the 
general hospital in Depok City from October to December 2017. 
Respondents were outpatients diagnosed with T2DM receiving routine 
care at the general hospital in Depok City, with the National Health 
Insurance, using pharmacological therapy for the previous 3 months or 
longer, and had poor glycemic control based on their medical record. 
Those with hemoglobinopathy and mental disorders and who were 
pregnant and lactating were excluded from the study.
The study obtained an ethical license from the Medical Research Ethics 
Committee of the Faculty of Medicine, University of Indonesia. Those 
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who meet the inclusion criteria and were willing to be take part in the 
study gave written informed consent.
The sample size was calculated by estimating the proportion of 
the population, and the sample obtained was at least 96 patients 
(Equation 1) [17]. Sample determination was carried out using 
consecutive method sampling. Each participant performed a glycemic 
control assessment using HbA1c levels, and QoL was assessed using the 
validated EQ-5D-5L Indonesian version (Euroqol). The study obtained 
permission from Euroqol to use EQ-5D-5L.









Z1−∝/2=Signification level α 0.05
d=Sampling error 10%
EQ-5D-5L was used as a self-administered questionnaire to give a 
better perspective of the respondents. EQ-5D-5L consists of QoL values 
using a descriptive questionnaire and visual analog scale (VAS) score to 
quantitatively assess the QoL on the day of measurement. QoL values 
were assessed using the five dimensions of mobility, self-care, usual 
activities, pain/discomfort, and anxiety/depression (sadness), with five 
levels of assessment ranging from 1 (no difficulty) to 5 (inability) for 
each dimension. The VAS score ranged from 0 (worst health imaginable) 
to 100 (best imaginable health) [10]. Descriptive data were translated 
to quantitative data using the Indonesian value set scale of 0 (death) to 
1 (full health) [15].
Data were analyzed using Statistical Package for the Social Sciences 
(SPSS) version 21, and advanced calculations used univariate, bivariate, 
and multivariate analyses. Univariate analysis was used to measure 
mean, standard deviation, 95% confidence interval, and qualitative 
and quantitative variables. Bivariate analysis was used to assess the 
correlation between variables with non-parametric tests (Mann–
Whitney U-test or Kruskal–Wallis test) for continuous variables and 
Spearman’s rho test for categorical variables after the normality of the 
data was checked. Multivariate analysis was used to model the association 
between the QoL (QoL values and VAS score) and sociodemographic 
and clinical factors. A 5% (p<0.05) level of significance was established 
to eliminate the null hypothesis. Independent variables, such as the use 
of an adherence assessment using a pill count test, as well as diet and 
physical activity, were assessed by a nutritionist at the hospital.
RESULTS
At the end of 2017, there were 746 outpatients with T2DM at the general 
hospital in Depok City; however, only 111 of these fulfilled the inclusion 
criteria. One patient had a mental disorder and two were unwilling to 
participate, resulting in a total sample of 108 patients.
The demographics and clinical characteristics of the patients with 
T2DM were performed by descriptive analysis (Table 1). Most (63 
people, 58.3%) of the respondents were not the elderly, 74 (68.5%) 
were women, 57 (52.8%) had a low level of education, and 80 (74.1%) 
were unemployed. The clinical characteristics of patients with T2DM 
included 49 patients (45.4%) with a duration of disease of 1–5 years, 
43 patients (39.8%) without comorbidities, 51 patients (47.2%) 
with a history of DM, 60 patients (55.6%) with non-adherence to DM 
treatment, 83 patients (76.9%) without experience of adverse effects 
of DM, 57 patients (52.8 %) not adhering to the recommended diet 
regimen for DM patients, 49 patients (45.4%) performing physical 
activity as recommended for DM patients, and 67 patients (62.0%) did 
not meet the glycemic control target. HbA1c levels were affected by age 
(p=0.004), HbA1c levels were affected by age (p=0.005), adherence 
(0.016), glycemic control (p=0.000), diet (p=0.000) and physical 
activity (p=0.000).
T2DM therapy used by the patients at the general hospital in Depok City 
included oral and insulin therapy, as well as single use and combination 
therapy (Table 2). The most frequent single drug used was metformin 
(5.6%), whereas the most common combination therapies were a 
two-drug combination of metformin and sulfonylurea (32.4%) and a 
three-drug combination of metformin, sulfonylurea, and α-glucosidase 
inhibitors (29.6%). Insulin therapy was generally combined with 
oral therapy (7.4%). T2DM therapy for glycemic control and the best 
VAS values were achieved using a combination of metformin and 
sulfonylurea (HbA1c 7.16% and VAS 70.64), while the highest QoL 
value (0.83) was achieved using a combination of metformin and 
α-glucosidase inhibitors.
The QoL of patients with T2DM at the general hospital in Depok City was 
assessed using the validated EQ-5D-5L in Indonesian language. The EQ-
5D-5L consists of QoL values and VAS scores. QoL was assessed using 
Five dimensions: mobility, self care, usual activity, pain/discomfort, and 
anxiety/depression (sadness) (Table 3). The mean value for the QoL 
was 0.74±0.23, while the mean VAS score was 65.49±15.96.
Table 4 shows descriptive data for QoL based on patient characteristics 
of T2DM. The QoL and VAS values of T2DM patients were higher in 
non-geriatric patients, those who were active at work had a duration 
of DM of <1 year, adhered to DM therapy, and did not follow non-
pharmacological treatment recommendations.
The QoL of T2DM patients was different for all dimensions. Anxiety/
depression was affected by duration of T2DM, adverse effects, and 
physical activity of the patient, while mobility and discomfort were 
affected by employment status. Self-care and usual activities were not 
influenced by clinical factors (Table 5). The association between the 
value of QoL and VAS score with sociodemographic and clinical factors 
was assessed by linear regression analysis (Table 6). The QoL value was 
influenced by HbA1c value, DM duration, and physical activity (p=0.008, 
R2=10.6%). The VAS values were influenced by HbA1c and DM duration 
(p=0.003, R2=10.3%).
DISCUSSION
In the present study, 108 outpatients with T2DM had an average HbA1c 
of 7.99±1.89. Patients were included in this study based on factors 
that influence glycemic control, such as DM-targeted therapy. Previous 
studies showed that HbA1c levels are influenced by gender, ethnicity, 
health insurance, DM duration, physical activity, and understanding 
of language [6-8]. In this study, health insurance and understanding 
of language were not included as independent factors because most 
patients in Depok City already have national health insurance and 
understand Indonesian languages.
The demographic and clinical characteristics of patients with T2DM 
were assessed through descriptive analyses and using SPSS version 21. 
The demographic characteristics of the participants, including 
nonelderly age, female, low education level, and inactive work life, were 
similar to the findings of Rwegerara et al., showing that the majority 
of DM patients were women (69.5%), had a first-degree education 
(47.6%), were <54 years of age (41.8%), and had a disease duration of 
<5 years (49.2%). Vidal-Peracho et al. also observed that the majority of 
patients with T2DM were female (74%) and inactive (89.6%) [18-19].
The majority of participants did not have a coexisting disease (39.8%), and 
the study site was a secondary level health-care facility. Patients requiring 
drugs outside the medicine list of primary health care facilities were 
recommended to secondary health facilities. The clinical characteristics 
of the participants who were on non-pharmacological therapy, namely 
diet and exercise, were similar to those observed by Vidal-Peracho et al. 
The majority of patients performed the physical activity as directed but 
did not follow an appropriate diet for patients with DM [19].
Correlations were analyzed between HbA1c and age, gender, education 
level, occupational status, DM duration, comorbidities, family history of DM, 
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DM treatment adherence, side effects, glycemic control, diet, and physical 
activity. Among the participants, HbA1c levels were influenced by age, DM 
disease duration, DM treatment adherence, glycemic control, diet, and 
physical activity suitable for patients with DM. Ostgren et al. demonstrated 
a significant correlation between DM duration and HbA1c levels (p<0.001). 
The association between DM duration and HbA1c is related to the patient’s 
ability to perform self-care, especially diet regulation, physical activity, 
drug use, and control of blood glucose levels [20].
Single-drug therapy is the first-line treatment for T2DM, and the most 
commonly used drug is metformin as it has a long-term safety profile 
and is well tolerated by most patients [13]. Metformin can help patients’ 
lose weight, and gastrointestinal tract side effects can be avoided by 
consumption after meals.
QoL was measured using a value set of EQ-5D-5L in Indonesian language, 
which was tested in 1054 respondents in Indonesia in a study by Purba 
et al. The result of this study showed that the value set could be used as a 
health and life quality measurement tool in Indonesia [15]. The average 
of QoL value was 0.74±0.23, ranging from 0 (worst QoL) to 1 (perfect 
QoL). In addition, the patients’ mean VAS score was 65.49±15.96, ranging 
from 0 (best imaginable health) to 100 (worst health imaginable). The 
Table 1: Characteristic distribution of T2DM patients
Variable Categories n (%) Mean HbA1c (SD) p value
Age Non-geriatric 63 (58.3) 8.42 (2.08) 0.005*
Geriatric 45 (41.7) 7.36 (1.34)
Gender Female 74 (68.5) 8.19 (2.00) 0.115
Male 34 (31.5) 7.56 (1.55)
Education levels Low 57 (52.8) 8.17 (2.14) 0.717
Intermediate 34 (31.5) 7.76 (1.58)
High 17 (15.7) 7.89 (1.53)
Employment status Not working 80 (74.1) 7.87 (1.92) 0.136
Working 28 (25.9) 8.37 (1.78)
Duration (years) <1 13 (12.0) 7.71 (1.77) 0.106
1–5s 49 (45.4) 7.67 (1.76)
>5 46 (42.6) 8.43 (2.00)
Comorbidities 0 43 (39.8) 8.11 (2.07) 0.648
1 30 (27.8) 8.29 (2.07)
2 18 (16.7) 7.74 (1.37)
3 13 (12.0) 7.44 (1.69)
4 2 (1.9) 6.90 (0.99)
5 2 (1.9) a
History of DM Yes 51 (47.2) 7.97 (1.69) 0.889
No 50 (46.3) 8.03 (2.12)
Do not know 7 (6.5) 7.94 (1.72)
Adherence No 60 (55.6) 8.40 (2.01) 0.016*
Yes 48 (44.4) 7.49 (1.61)
Adverse effect Yes 25 (23.1) 7.78 (1.66) 0.582
No 83 (76.9) 8.06 (1.96)
Diet Yes 57 (52.8) 7.28 (1.39) 0.000**
No 51 (47.2) 8.79 (2.06)
Physical activity Yes 49 (45.4) 6.54 (0.68) 0.000**
No 59 (54.6) 9.20 (1.71)
Glycemic control HbA1c ≤ 7.0 41 (38.0) 6.30 (0.52) 0.000**
HbA1c > 7.0 67 (62.0) 9.04 (1.65)
Mean HbA1c±SD 7.99±1.89
SD: Standard deviation; aHbA1c levels for five comorbidities were constant and statistically eliminated. Statistical test using non-parametric test (Mann–Whitney U-test 
or Kruskal–Wallis test). *Correlation is significant at the 0.05 level (2-tailed). **Correlation is significant at the 0.01 level (2-tailed). T2DM: Type 2 diabetes mellitus, 
Hb: Hemoglobin
Table 2: Distribution of drug use for DM treatment in patients with T2DM (n=108)
Therapy n (%) Mean HbA1c (SD) QoL value (SD) VAS (SD)
Oral monotherapy
Biguanide 6 (5.6) 7.72 (1.59) 0.79 (0.17) 69.17 (8.01)
Sulfonylurea 3 (2.8) 7.97 (2.54) 0.59 (0.63) 53.33 (40.41)
α-Glucosidase Inhibitor 1 (0.9) 13.40 0.92 55.00
Oral combination therapy
Biguanide+Sulfonylurea 35 (32,4) 7.16 (1.10) 0.76 (0.21) 70.64 (14.99)
Biguanide+α-Glucosidase inhibitor 2 (1,9) 8.83 (0.87) 0.83 (0.15) 64.33 (22.28)
Sulfonylurea+α-Glucosidase inhibitor 9 (8,3) 8.23 (2.27) 0.77 (0.15) 61.88 (13.34)
Biguanide+Sulfonylurea+α-Glucosidase inhibitor 32 (29.6) 7.98 (2.11) 0.73 (0.22) 65.69 (15.26)
Insulin therapy
Insulin 7 (6.5) 9.76 (0.60) 0.68 (0.33) 59.29 (15.39)
Insulin+Biguanide 8 (7.4) 8.59 (1.00) 0.70 (0.19) 60.00 (11.95)
Insulin+Sulfonylurea 1 (0.9) 9.50 1.00 70.00
Insulin+α-Glucosidase inhibitor 2 (1.9) 8.20 (1.13) 0.77 (0.04) 60.00 (14.14)
Insulin+Biguanide+Sulfonylurea 1 (0.9) 12.4 0.82 30.00
Insulin+Biguanide+Sulfonylurea+α-Glucosidase inhibitor 1 (0.9) 11.50 0.22 45.00
SD: Standard deviation, QoL: Quality of life, T2DM: Type 2 diabetes mellitus, Hb: Hemoglobin, VAS: Visual analog scale
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Table 3: Quality of life of T2DM patients at Depok City Hospital (n=108)
Quality of life dimensions n (%) Mean±SD
No Problems (1) Slight problems (2) Moderate problems (3) Severe problems (4) Unable (5)
Mobility 60 (55.6) 29 (26.8) 14 (13.0) 5 (4.6) 0 (0) 1.67±0.88
Self care 90 (83.4) 13 (12.0) 5 (4.6) 0 (0) 0 (0) 1.21±0.51
Usual activities 78 (72.2) 19 (17.6) 11 (10.2) 0 (0) 0 (0) 1.38±0.66
Pain/discomfort 38 (35.2) 45 (41.7) 15 (13.9) 10 (9.2) 0 (0) 1.97±0.93
Anxiety/depression 45 (41.7) 40 (37.0) 14 (13.0) 8 (7.4) 1 (0.9) 1.89±0.23
Mean quality of life value 0.74±0.23
Mean VAS score 65.49±15.96
SD: Standard deviation. T2DM: Type 2 diabetes mellitus, VAS: Visual analog scale
Table 4: Descriptive analysis of characteristics and quality of life T2DM patients
Variable Categories QoL value±SD VAS±SD
Age Non-geriatric 0.75±0.22 66.54±14.99
Geriatric 0.72±0.25 63.91±17.39
Gender Female 0.78±0.19 64.50±17.22
Male 0.72±0.24 65.95±15.45
Education levels Low 0.72±0.23 63.86±15.95
Intermediate 0.72±0.25 67.96±15.54
High 0.85±0.18 67.18±17.19
Employment status Not working 0.81±0.20 66.86±16.26
Working 0.72±0.24 65.01-15.93
Duration (years) <1 0.79±0.13 78.69±8.20
1–5 0.72±0.24 64.94±15.42
>5 0.75±0.25 62.35±16.55
Comorbidities 0 0.77±0.17 65.72±13.35
1 0.74±0.25 66.00±16.83
2 0.68±0.32 66.50±19.80
3 0.74±0.24 60.77±18.00 
4 0.89±0.14 75.00±21.21
5 0.48±0.25 65.00±7.07
History of DM Yes 0.72±0.21 66.03±15.47
No 0.78±0.22 65.28±16.96
Do not know 0.54±0.3 64.29±13.97
Adherence No 0.77±0.19 67.14±15.05
Yes 0.71±0.25 64.17±16.66
Adverse effect No 0.68±0.26 66.12±18.94
Yes 0.76±0.22 65.30±15.08
Diet No 0.70±0.26 63.78±16.77
Yes 0.77±0.20 67.02±15.19
Physical activity No 0.73±0.21 64.03±13.11
Yes 0.76±0.26 67.24±18.84
QoL: Quality of life, SD: Standard deviation, CI: Confidence interval, T2DM: Type 2 diabetes mellitus, VAS: Visual analog scale
Table 5: Correlation characteristics and quality of life of T2DM patients
Variable p value
Quality of life dimensions QoL value VAS
Mobility Self‑care Usual activities Pain/discomfort Anxiety/depression
Age 0.079 0.800 0.364 0.336 0.501 0.591 0.477
Gender 0.043* 0.309 0.716 0.430 0.795 0.259 0.588
Education levels 0.064 0.318 0.076 0.131 0.364 0.061 0.434
Employment status 0.033* 0.107 0.189 0.037* 0.364 0.068 0.713
History of DM 0.992 0.463 0.790 0.918 0.234 0.046* 0.925
Duration of DM 0.301 0.286 0.996 0.931 0.008 ** 0.739 0.002**
Comorbidities 0.096 0.528 0.420 0.528 0.127 0.587 0.752
Adverse effect 0.672 0.573 0.501 0.141 0.008** 0.109 0.556
Adherence 0.285 0.318 0.159 0.234 0.448 0.325 0.458
Diet 0.156 0.917 0.882 0.347 0.144 0.195 0.412
Physical activity 0.873 0.297 0.910 0.091 0.046* 0.215 0.161
Statistical test by non-parametric test (Mann–Whitney U-test or Kruskal–Wallis test) for continuous variables and Spearman’s rho test for categorical variables. 
*Correlation is significant at the 0.05 level (2-tailed). **Correlation is significant at the 0.01 level (2-tailed). QoL: Quality of life, T2DM: Type 2 diabetes mellitus, 
VAS: Visual analog scale
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QoL of T2DM patients was 0.724 (range, 0–1) and 0.720 (range, 0–1) 
using EQ-5D-3L and EQ-5D-5L instruments, respectively. Compared with 
EQ-5D-3L, the EQ-5D-5L version had higher H′ in all dimensions, and it 
was concluded that the EQ-5D-5L version was more discriminative than 
the EQ-5D-3L version [5]. The QoL of patients assessed using the COOP-
WONCA instrument was 18.7 (range, 7–35) [19].
The QoL of patients with DM was influenced by HbA1c levels, duration 
of DM, and physical activity, while the VAS was significantly affected 
by HbA1c levels and duration of DM. Similar results were observed by 
Kuznetsov, L., Griffin, S., Davies, H., Lauritzen, T., Khunti, K., Rutten, G., 
Simmons, R who showed that QoL and duration of DM were associated 
with HbA1c levels [21]. Previous studies on QoL showed that patients 
with T2DM can be influenced by self-care behaviors, including nutrition 
and blood glucose control. Among the self-care behaviors, nutrition 
may be the most important predictive factor [22]. In the present study, 
diet, as suggested by a nutritionist, did not influence either the value of 
QoL or VAS score.
QoL values obtained using the EQ-5D-5L instrument were derived from 
a descriptive questionnaire and were not always consistent with VAS 
scores. A previous study using EQ-5D and EQ-VAS questionnaires on 
the quality-adjusted life year of diabetic retinopathy patients had more 
significant VAS score results compared with assessment using the EQ-
5D descriptive questionnaire [23]. In the present study, differences were 
seen between the QoL value and VAS score and the factors associated 
with QoL. This shows that the QoL value should not always be based on 
a descriptive questionnaire, as the VAS score can generate results in line 
with the QoL value because the methods used are different.
The present study had certain limitations. The study was cross-sectional 
and further constrained by the elimination criteria and targeted only 
those with T2DM. From a population of 746 at the hospital, only 
108 patients were included.
CONCLUSION
The QoL values of patients with DM were influenced by HbA1c 
levels, duration of DM, and physical activity, while the VAS score was 
significantly affected by HbA1c levels and duration of DM. Anxiety/
depression was affected by the duration of T2DM, adverse effects, and 
physical activity of the patient, while mobility and discomfort were 
affected by employment status. Self-care and usual activities were not 
influenced by clinical factors, while HbA1c levels were influenced by 
age, DM disease duration, DM treatment adherence, glycemic control, 
diet, and physical activity suitable for patients with DM.
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Table 6: Linear regression model of the quality of life
Model R2 Standardized coefficient β p value
Quality of life value 10.6 0.008
HbA1c levels −0.226 0.090
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VAS value 10.3 0.003
HbA1c levels −0.170 0.072
Duration of DM −0.244 0.011
DM: Diabetes mellitus, VAS: Visual analog scale, HB: Hemoglobin
